Cystadenocarcinoma

A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)

Also Known As:

Networked: 238 relevant articles (4 outcomes, 15 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Cholangiocarcinoma
3.	Cystadenoma
4.	Cysts
5.	Adenocarcinoma

Experts

1.	Zen, Yoh: 3 articles (11/2011 - 09/2006)
2.	Nakanuma, Yasuni: 3 articles (11/2011 - 09/2006)
3.	Lim, Jae Hoon: 2 articles (11/2011 - 01/2002)
4.	Mizuguchi, Yasunori: 2 articles (09/2010 - 08/2003)
5.	Kinoshita, Hiroaki: 2 articles (12/2003 - 01/2003)
6.	Uenishi, Takahiro: 2 articles (12/2003 - 01/2003)
7.	Tanaka, Shogo: 2 articles (12/2003 - 01/2003)
8.	Hai, Seikan: 2 articles (12/2003 - 01/2003)
9.	Hirohashi, Kazuhiro: 2 articles (12/2003 - 01/2003)
10.	Yamamoto, Takatsugu: 2 articles (12/2003 - 01/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Cystadenocarcinoma:

1.	MucinsIBA 01/01/1983 - "Absorption of the antiserum with mucinous ovarian cystadenocarcinoma fluid eliminated generalized mucin staining, and only pancreatic ducts and colonic goblet cells were positive. " 01/01/1997 - "Histologically, the cystic component was lined by mucin-producing, columnar to cuboidal epithelium composed of benign to atypical to overtly malignant cells (cystadenocarcinoma). " 05/15/1992 - "Nine cases of biliary cystadenocarcinoma of the liver were studied, with emphasis on its clinicopathologic features, mucin profiles, and immunohistochemical characteristics. " 07/01/2007 - "The resection margins were free of tumor, and the histological study showed a mucinous pancreatic cystadenocarcinoma with mucin-producing columnar epithelium and associated papillae patterns, reminiscent of ovarian stroma. " 03/15/1999 - "In each Cox regression model, both those including cystadenocarcinoma and mucin-producing tumors and those that did not, p27Kip1 expression proved to be an independent predictor for overall survival by multivariate analysis. "
2.	AntigensIBA 08/01/1983 - "Tumour-associated antigens for cystadenocarcinoma of the ovary." 03/01/1981 - "Only one of five mucinous ovarian cystadenocarcinomas was positive for colonic mucoprotein antigen. " 03/01/1981 - "An antiserum prepared against normal colon-derived colonic mucoprotein antigen and appropriately absorbed with mucinous ovarian cystadenocarcinoma fluid had reactivity limited to the colon and cecum when tested by immunoperoxidase against various normal adult tissue specimens. " 02/01/1979 - "Circulating ovarian cystadenocarcinoma-associated antigen serum levels were positive in 69.8% of patients and correlated with response to chemotherapy in 70% of patients. " 10/15/1994 - "The detection of this antigen may help to identify serous ovarian tumors by distinguishing tumors of low malignancy from cystadenocarcinomas."
3.	HormonesIBA 01/01/1983 - "Progestin treatment was effective in cases of endometrioid cystadenocarcinoma, particularly, in those of hormone-producing form." 07/01/2007 - "Mucinous cystadenocarcinoma is the most frequent pancreatic cystadenocarcinoma and it is mainly seen in women, suggesting a sex hormone influence. " 01/01/1984 - "Neuron-specific enolase was present in peptide hormone-producing endocrine cells outside the pituitary and in their tumors; the majority of other tumors were negative for NSE, although one breast carcinoma, one ovarian cystadenocarcinoma, and one lymphoma were positive for NSE. "
4.	Mucin-1 (CA 15-3 Antigen)IBA 12/01/1999 - "Our previous immunohistochemical study on intrahepatic bile duct tumors showed that invasive cholangiocarcinoma (ICC) with a poor outcome expressed MUC1 mucin but was negative for MUC2 mucin, whereas bile duct cystadenocarcinoma (BDCC) with a favorable outcome was MUC1 negative and MUC2 positive. " 12/01/1997 - "In the present study of pancreas and intrahepatic bile duct tumors, MUC1 mucin (membrane bound mucin detected by monoclonal antibody, DF3) was highly expressed in invasive ductal carcinomas of the pancreas (IDC) and invasive cholangiocarcinomas of the liver (ICC), which show invasive growth and a poor prognosis, but it was rarely expressed in intraductal papillary mucinous tumors of the pancreas (IPMT) and bile duct cystadenocarcinomas of the liver (BDCC), which show a favorable prognosis. " 05/01/1989 - "Cryostat sections of human skin were stained with monoclonal antibodies to involucrin, a range of cytokeratins, epithelial membrane antigen (EMA), and an ovarian cystadenocarcinoma antibody (OM1) to identify combinations of antibodies that could be used to discriminate between basal and differentiated sebocytes and other cell types present in the pilosebaceous unit. "
5.	Protein Isoforms (Isoforms)IBA 01/01/2012 - "In this study, we examined the expression of all isoforms of CD44 by immunohistochemistry in 3 cases of biliary cystadenoma, 15 cases of non-invasive cystadenocarcinoma (CAC) bile duct tumors, and 67 cases of the aggressive bile duct tumor, cholangiocarcinoma (CCA). " 12/01/2003 - "Expression of transforming growth factor-beta isoforms in the skin, kidney, pancreas and bladder in a German shepherd dog affected by renal cystadenocarcinoma and nodular dermatofibrosis." 12/01/2003 - "The present study was performed to assess the expression of isoforms 1, 2 and 3 of transforming growth factor (TGF)-beta in skin nodular dermatofibrosis lesions, kidney, bladder and pancreas from a 10-year-old female German shepherd dog (GSD) affected by renal cystadenocarcinoma and nodular dermatofibrosis (RCND) compared with normal GSDs (n = 2). "
6.	Carcinoembryonic AntigenIBA 02/01/2007 - "We compared endoscopic ultrasonography-guided (EUS-guided) fine needle aspiration biopsy combined with cyst fluid carcinoembryonic antigen (CEA), CA19-9 examination with computed tomography (CT), B-ultrasonography (B-US) and serum CEA and CA19-9, to explore methods of early diagnosis of cystadenocarcinoma of the pancreas. " 04/01/1998 - "A carcinoembryonic antigen level of >400 ng/ml had a 57% sensitivity and a 100% specificity for distinguishing mucinous tumours and cystadenocarcinomas from pseudocysts. " 08/01/1978 - "Cystadenocarcinoma and carcinoembryonic antigen (CEA)." 01/01/1986 - "Cystadenoma and cystadenocarcinoma of the liver: localization of carcinoembryonic antigen." 06/01/1978 - "Carcinoembryonic antigen in ovarian epithelial cystadenocarcinomas: the prognostic value of tumor and serial plasma determinations."
7.	Biological Tumor Markers (Tumor Markers)IBA 11/01/2008 - "It is also difficult to differentiate biliary cystadenoma from biliary cystadenocarcinoma preoperatively by imaging studies or tumor markers. " 01/01/2006 - "But tumor markers cannot distinguish cystadenocarcinoma from cystadenoma or both from other cystic lesions of liver. " 02/15/1982 - "it was concluded that primitive cells in inclusion cysts elaborate the same tumor markers found in serous cystadenoma and cystadenocarcinoma of the ovary. " 07/01/1983 - "The following serum tumor markers are elevated above normal levels in 50 percent or more of patients with various malignant neoplasms: Alpha-fetoprotein in yolk sac tumors, hepatomas, retinoblastomas, embryonal carcinomas, breast carcinomas, and carcinomas of uterine cervix; Carcinoembryonic antigen in colon carcinomas, choriocarcinomas, pancreatic carcinomas, medullary thyroid carcinomas, osteosarcomas, retinoblastomas, ovarian cystadenocarcinomas, mycosis fungoides, hepatomas, esophageal carcinomas, adenocarcinomas of uterine cervix, lung carcinomas, carcinomas of small intestine, urinary bladder carcinomas, and renal cell carcinomas; Human chorionic gonadotrophin in choriocarcinomas, malignant interstitial cell tumors of testis, non seminomatous tumors of testis, embryonal carcinomas, and pancreatic carcinomas. "
8.	DNA (Deoxyribonucleic Acid)IBA 12/01/1995 - "To study nuclear DNA content and morphological parameters in ovarian cystadenocarcinoma. " 12/01/1995 - "[A quantitative study on nuclear DNA content and morphological parameters in ovarian cystadenocarcinoma]." 12/01/1995 - "Nuclear DNA content of ovarian cystadenocarcinoma is a useful marker in reflecting the biological behavior and is of practical value in diagnosis, the choice of treatment methods and in the evaluation of results and prognosis." 12/01/1995 - "Nuclear DNA content of ovarian cystadenocarcinoma was related to its histopathological classification, histological grade and clinical stages (P < 0.01, P < 0.05). " 12/01/1995 - "DNA content of ovarian cystadenocarcinoma was the highest among the three groups; and there were significant differences between the groups (P < 0.01). "
9.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/01/2002 - "The aim of this study was to investigate the expression of vascular endothelial growth factor (VEGF) by neoplastic cells in serous ovarian cystadenocarcinoma in relation to proliferation as determined by mitotic activity and to FIGO stage. " 01/01/2002 - "VEGF expression as determined by immunohistochemistry is related to high mitotic activity and high FIGO stage in serous ovarian cystadenocarcinomas. "
10.	NeopterinIBA 04/27/1999 - "In this prospective clinical study serum neopterin values were evaluated in 83 patients with adenocarcinoma of the pancreas (PC), 47 patients with chronic pancreatitis (CP), 8 patients with cystadenocarcinoma (CA) of the pancreas and 24 healthy controls (HC). "

Therapies and Procedures

1.	Hepatectomy 05/01/2011 - "The mainstay of treatment is complete resection, either by enucleation or by formal hepatectomy, since incomplete removal entails not only constant recurrence but also the risk of malignant transformation to cystadenocarcinoma. " 01/01/2013 - "We preoperatively diagnosed this lesion as cystadenocarcinoma or CE and performed a left hepatectomy. " 03/01/2003 - "An extended left hepatectomy was performed on the basis of a presumptive diagnosis of a cystadenocarcinoma. " 01/01/2001 - "Systematic hepatectomy was recommended as the initial treatment in consideration of the features of cystadenocarcinoma." 07/01/1996 - "Biliary cystadenocarcinoma resected by segment 3 and 4 hepatectomy."
2.	Laparotomy 01/01/2010 - "The aim of this study was to assess management of a consecutive series of patients who underwent laparotomy for a suspected cystadenoma or cystadenocarcinoma. " 01/01/2014 - "On the presumptive diagnosis of a cystadenoma or cystadenocarcinoma, patient underwent laparotomy. " 03/01/2010 - "On diagnostic laparotomy peritoneal infiltrations were observed and pathologic examination revealed a biliary cystadenocarcinoma and peritonitis carcinomatosa was diagnosed. " 10/01/2004 - "In the previous 12 patients managed with laparotomy, 6/12 patients had biliary epithelium alone; the other 6 also contained MS with 1 patient exhibiting intestinal metaplasia and cystadenocarcinoma. " 01/01/1990 - "The authors present a case history of a patient whose most recent relapse occurred 7 years after the initial laparotomy carried out for bilateral ovarian stage III cystadenocarcinoma diagnosed by biological follow-up (CA 125) which occurred because of isolated splenic metastases which were identified thanks to ultrasound examination. "
3.	Pancreatectomy 04/01/1998 - "There was also a cystic lesion in the pancreas, and subsequent distal pancreatectomy revealed a cystadenocarcinoma of the pancreas. " 09/01/1991 - "A distal pancreatectomy was performed after a diagnosis of cystadenocarcinoma. " 01/01/1987 - "Total pancreatectomy was performed under the diagnosis of cystadenocarcinoma. " 06/01/1985 - "[An autopsy performed on a pancreatic cystadenocarcinoma patient who received total pancreatectomy ten years ago]." 05/30/1981 - "Total excision of a cystadenocarcinoma in a third case required 90% pancreatectomy with ensuing diabetes. "
4.	Drug Therapy (Chemotherapy) 01/01/1999 - "Huge biliary cystadenocarcinoma occupying the right lobe of the liver measuring 12 cm in size before chemotherapy was drastically decreased to 2 cm in size 8 months after chemotherapy. " 05/01/1991 - "Cytoreductive surgery and intraperitoneal chemotherapy with peritoneal spread of cystadenocarcinoma." 01/01/1990 - "The unique clinical features of cystadenocarcinoma were reviewed and the particular suitability of intraperitoneal chemotherapy for its treatment was discussed. " 01/01/1990 - "Cystadenocarcinoma of the pancreas is generally considered to be unresponsive to chemotherapy and radiation therapy. " 01/01/1989 - "New surgical technologies combined with postoperative intraperitoneal chemotherapy have been shown to be curative for selected patients with recurrent cystadenocarcinoma. "
5.	Pancreaticoduodenectomy 10/01/2009 - "The patient underwent a pancreaticoduodenectomy, and histopathological examination revealed a locally invasive cystadenocarcinoma without metastatic disease. " 09/01/2008 - "The most frequent operation was partial duodenopancreatectomy (7) and most frequently cystadenocarcinoma was identified histologically (5 times). " 05/01/1974 - "Cystadenocarcinoma of pancreas with staged pancreatoduodenectomy." 06/01/2002 - "One patient, with cystadenocarcinoma, died from cancer recurrence 18 months after TP and 140 months after the initial pancreaticoduodenectomy. " 10/01/1991 - "A solid and cystic tumor (SCT) was located at the head of the pancreas in a 43-year-old Japanese male, and pancreatoduodenectomy was performed on the suspicion of papillary carcinoma or cystadenocarcinoma of the pancreas. "